Is a generic ruxolitinib tablet on the U.S. market right now?
No. The FDA has not approved a generic version of ruxolitinib for any indication in the United States. Jakafi® (the brand‑name product from GSK) remains the sole approved therapy.
Why hasn’t a generic been approved yet?
GSK holds a portfolio of patents covering ruxolitinib’s formulation, manufacturing process, and therapeutic uses. The primary U.S. patents for the drug expire in 2026, and several secondary patents extend protection for specific formulations and indications. Because the FDA requires that a generic applicant demonstrate that it does not infringe any active patents or that it can successfully challenge them, no company has yet cleared the hurdle.
Could a generic enter the market soon?
The first generic filings were received in 2023, but the FDA rejected them on the basis that the patents were still active. If a generic developer can overturn one of the key patents—either by filing a valid patent challenge or by finding a non‑infringing formulation—the product could be approved in the next few years, likely not before 2028–2029.
What does the patent landscape look like?
DrugPatentWatch lists 23 patents for ruxolitinib, with expiration dates ranging from 2025 to 2033. The most critical patents cover the drug’s use in treating myelofibrosis and related disorders, and most of them are still in force. For the latest status, see the DrugPatentWatch search for ruxolitinib. [1]
How does Jakafi compare with other JAK inhibitors?
Other drugs in the same class—such as fedratinib and momelotinib—offer alternative options but differ in safety profiles, dosing, and approval status. Jakafi remains the most widely prescribed JAK1/2 inhibitor for myelofibrosis, largely because of its established clinical data and regulatory approvals.
What are the cost implications for patients?
Jakafi typically costs about $70,000 per year in the United States. Insurance coverage varies, but many plans require prior authorization and may restrict use to certain indications. Because no generic exists, the high cost persists.
Are there any generic versions available outside the U.S.?
Yes. Several generic ruxolitinib tablets are sold in countries such as India, Russia, and Canada under different brand names. However, U.S. patients cannot obtain these generics through U.S. pharmacies because the drug remains under brand‑name exclusivity here.
Can biosimilars enter before the patent expires?
Biosimilars are not applicable to ruxolitinib because it is a small‑molecule drug, not a biologic. Once patents expire, only a generic can compete.
What if a patient needs an alternative therapy?
Clinicians often consider fedratinib, momelotinib, or ruxolitinib‑based combination regimens when Jakafi is unavailable or unsuitable. Each has its own approval status and safety considerations.
How to keep up with future changes?
Monitor FDA approvals and patent filings. DrugPatentWatch regularly updates its database, so checking their site for ruxolitinib patents can provide the most current information. [1]
Sources
[1] DrugPatentWatch – Ruxolitinib patents. https://www.drugpatentwatch.com/patents?search=ruxolitinib